Background Patients with prior pancreaticobiliary or distal gastric cancer treated surgically may have local anastomotic recurrence with obstruction of the afferent and efferent jejunal limbs. This report describes the efficacy and safety of simultaneous endoscopic insertion of selfexpanding metal stents into the afferent and efferent jejunal limbs in patients with gastric outlet obstruction (GOO) of post-surgical anatomy for palliation of recurrent malignancy. Methods Patients were identified from an endoscopic database at a specialized cancer center between September 2007 and March 2014. Technical success was defined as single-session insertion of afferent and efferent jejunal limb enteral stents. Clinical success was defined as immediate symptom relief and ability to advance diet. A durable response was defined as symptom relief of at least 60 days or until hospice placement or death. Results Twenty-three patients were identified who underwent insertion of two 22-mm-diameter uncovered duodenal stents. Stent length varied from 60 to 120 mm. Stents were placed under endoscopic and fluoroscopic guidance. Three patients required balloon dilation to facilitate stent insertion. Average procedure time was 58.8 min (range 28-120). Technical success was achieved in 23/24 (96 %) patients. Clinical success was achieved in 19/23 (83 %) patients. Following initial stent insertion and prior to subsequent re-intervention, 11/19 (58 %) patients had a durable response with a median duration of 70 days (range 4-315). Eight (42 %) patients underwent subsequent reintervention at a median of 22 days (range 11-315). Five patients had stent revision and were able to tolerate oral intake. Two patients had percutaneous endoscopic gastrostomy/jejunostomy insertion. One patient required surgical diversion for persistent obstruction. Complications included stent migration and post-stent insertion bacteremia due to food bolus obstruction. Conclusions Recurrent malignant GOO in patients with post-surgical anatomy treated with simultaneous endoscopic enteral stenting of afferent and efferent jejunal limbs has a high rate of technical and clinical success and low rate of complications and provides effective palliation.
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Keywords Gastrojejunostomy Á Enteral stent Á Endoscopic palliation Á Pancreaticobiliary cancer Á Gastric cancer Á Malignant gastric outlet obstruction Symptom palliation from malignant gastrointestinal (GI) obstruction is a well-accepted indication for endoscopic insertion of self-expanding metal stents (SEMS). SEMS have been placed to treat esophageal, biliary, gastric, duodenal and colonic obstructions [1] [2] [3] [4] .
Surgical treatment of patients with resectable pancreaticobiliary or distal gastric cancer commonly includes creation of afferent and efferent jejunal limbs. Patients may have local recurrence of disease with subsequent malignant obstruction of the afferent and efferent jejunal limbs at the level of the anastomosis. This results in symptomatic gastric outlet obstruction (GOO), with patients commonly presenting with nausea, vomiting, abdominal pain, distention and inability to eat per os. Some cases may also be complicated by cholangitis, due to impaired drainage of the distended, bile-filled, obstructed afferent jejunal limb. As in patients with other causes of malignant GI obstruction, endoscopic insertion of SEMS may also be used for palliation in patients with postoperative anatomy and obstructed afferent/efferent jejunal limbs from recurrent malignant disease. Simultaneous insertion of two SEMS through an obstructed anastomosis into each of the afferent and efferent jejunal limbs is technically challenging as stent insertion into one limb may increase the difficulty of accessing and successfully stenting the other limb.
There is currently limited information on the efficacy and safety of simultaneous endoscopic insertion of afferent and efferent jejunal limb SEMS for GOO in patients with recurrent malignancy [5] [6] [7] [8] [9] [10] . Hence, we report our experience with this procedure at a specialized cancer center.
Materials and methods

Patients
Retrospective review of a prospective GI endoscopic database and the electronic medical record at Memorial Sloan Kettering Cancer Center (MSKCC) was completed for records from September 2007 to March 2014 to identify patients meeting the following inclusion criteria: (1) history of surgical treatment for pancreaticobiliary or distal gastric malignancy with creation of afferent/efferent jejunal limbs; (2) clinical and radiographic evidence of gastric outlet obstruction; (3) endoscopic confirmation of recurrent malignant disease at the anastomosis; and (4) attempt at simultaneous endoscopic insertion of two enteral SEMS into both the afferent and efferent jejunal limbs across the obstructed gastrojejunostomy.
Information obtained from these databases and inpatient/outpatient medical records included: age, gender, primary cancer diagnosis, surgical resection type and date, symptoms pre-and post-stent insertion, radiological images, extent of recurrent malignant disease, treatment, stent insertion procedure details, clinical response to stent insertion, complications and follow-up management.
The study was approved by the MSKCC Institutional Review Board.
GI endoscopy
Patients were kept nothing per os for at least 8 h before the procedure. At time of endoscopy, patients underwent endotracheal intubation and received general anesthesia. Upper gastrointestinal endoscopy was performed using a GIF Type 1TQ160 endoscope (Olympus, Tokyo, Japan) with through the scope enteral stent placement via a 3.7-mm working channel.
Endoscopic SEMS placement
Characterization of the malignant gastrojejunal anastomotic stricture and enteral SEMS insertion was performed under both direct endoscopic and fluoroscopic guidance. If the endoscope was not able to traverse the anastomotic stricture, then guidewires were passed under fluoroscopic guidance. Two 0.035-in Jagwires (Boston Scientific, MA, USA) were advanced through the obstructed segment, one into each jejunal limb. In some cases, dilation of the anastomotic stricture was performed with a CRE wireguided balloon (Boston Scientific) to facilitate insertion of the enteral stents. Radiopaque markers were placed on the skin to document the location of the surgical anastomosis and distal end of each stricture.
The stents utilized were uncovered nitinol duodenal Wallflex stents (Boston Scientific) with a body diameter of 22 mm and flare of 27 mm, of varying lengths-60, 90 and 120 mm with a 10-Fr delivery system. The length of stent utilized was based on endoscopic and fluoroscopic findings, approximately 2-3 cm longer than the length of tumor stricture.
Two enteral SEMS were sequentially deployed across the anastomotic stricture. A minimum margin of 2 cm of non-strictured lumen at each stent end allowed for flaring and shortening following deployment. Final position and stent expansion was confirmed with abdominal radiographs post-stent insertion.
Technical success was defined as single-session insertion of both afferent and efferent jejunal limb enteral stents.
Clinical success was defined as immediate symptom relief and ability to advance diet.
A durable response was defined as either symptom relief of at least 60 days or effective palliation until hospice placement or death.
Statistical analysis
Results were expressed as descriptors, mean ± standard deviation, percentages or medians with ranges.
Results
Patient demographics
Sixteen of the 23 (70 %) patient were male. Complete patient demographics are shown in Table 1 .
Technical success
Technical success was achieved in 23/24 (96 %) patients. Three patients required balloon dilation of the anastomotic stricture (up to 15, 12 and 12 mm) to facilitate afferent jejunal limb SEMS insertion. Average procedure time was 58.8 min (range 28-120).
Clinical success
Initial clinical success
Initial clinical success was achieved in 19/23 (83 %) patients.
Four patients with successful SEMS placement failed to achieve immediate acceptable oral intake post-stent insertion. One patient underwent stent revision 5 days later for management of an obstructing food bolus that was lodged in the afferent jejunal limb stent. The food bolus was removed with a Roth Net retrieval device (US Endoscopy, OH, USA), followed by insertion of a new Wallstent 22 mm 9 120 mm placed coaxially within the preexisting 22 mm 9 90 mm efferent jejunal limb stent to facilitate preferential food movement into the efferent jejunal limb, as it was suspected that the afferent limb prosthesis was blocking the efferent jejunal limb stent. The patient's symptoms improved after food bolus disimpaction and stent revision. No further re-intervention was required up to 335 days of follow-up.
Of the remaining three non-responders, two patients had metastatic pancreatic cancer and one had metastatic gastric cancer. Two received a drainage percutaneous gastrostomy (PEG), and in both cases the enteral stents were noted to be patent at the time of endoscopy. The third patient declined drainage PEG.
Durable response
Following initial stent insertion, 11/19 (58 %) patients had a durable response, with a median duration of 70 days (range 4-315).
Six of 11 patients had effective palliation until time of death in hospital or discharge to home hospice (range 4-235). Three patients maintained stent patency for at least 60 days (range 76-140), before being lost to follow-up. Two patients maintained stent patency for at least 60 days (range 70-315), with subsequent need for stent revision.
Re-intervention
Eight of 19 (42 %) patients who demonstrated initial clinical success required re-intervention with either stent revision, PEG/PEJ insertion or surgery during follow-up at a median of 22 days (range 11-315).
Five of eight (63 %) patients had stent revision at a median of 22 days (range 19-315). All five attempts at stent revision were successful. See Table 2 for stent revision details. All patients were able to tolerate oral intake following stent revision. Duration of stent patency following revision lasted a median of 30 days (range 5-91); four of five patients with stent revision did not require further intervention up until the last day of follow-up. One patient received APC treatment of tumor overgrowth of stent at 5 days post-stent revision.
Two patients had a combination of drainage PEG and feeding percutaneous endoscopic jejunostomy (PEJ) inserted 17 and 22 days following stent insertion. All enteral stents were patent at the time of PEG/PEJ insertion.
One patient received surgical diversion with gastrojejunostomy, ileocolostomy and drainage gastrostomy tube because of persistent obstruction 11 days after stent insertion.
Complications
One patient had bacteremia that was attributed to obstruction of the afferent jejunal limb stent by an impacted food bolus felt related to afferent limb stent compression/ blockage of the efferent limb stent. The patient was treated with antibiotics, food bolus disimpaction and stent revision. One patient required afferent limb stent removal Impact of ascites and peritoneal disease on clinical success and feasibility of initiating/or continuing chemotherapy after SEMS placement
Eight of 19 (42 %) patients with initial clinical success had radiographic evidence of peritoneal disease, and eight (42 %) had ascites. Two of the initial non-responders had no peritoneal disease and small volume ascites, whereas the two other patients had peritoneal disease, one with small volume ascites and the other without. The initial non-responder treated with stent revision had no ascites with presence of peritoneal disease. Nine of 23 (39 %) patients were receiving chemotherapy at the time of stent insertion. Following stent insertion, five patients continued, four discontinued, and three initiated chemotherapy. For the four patients who discontinued chemotherapy, the decision to cease treatment was not stent related.
Discussion
There are limited data on the use of endoscopic placement of enteral SEMS for palliation of gastric outlet obstruction in patients with prior surgically created anastomosis with afferent/efferent limbs and recurrent malignancy.
Prior studies have focused mainly on comparison of endoscopic stenting compared to operative gastrojejunostomy for palliation of malignant gastric outlet obstruction in patients who had not undergone prior surgical resection of their primary pancreaticobiliary or distal gastric cancer [4, [10] [11] [12] [13] [14] [15] [16] . For our study, we included only those patients with recurrent malignant gastric outlet obstruction at the site of their postoperative afferent/efferent jejunal limb anastomosis.
We report a 96 % technical success rate and 83 % clinical success rate in patients treated with simultaneous endoscopic afferent and efferent limb enteric SEMS insertion. Patients who did not experience relief of symptoms were found to have patent stents on repeat endoscopic examination. This suggests that in some patients despite successful endoscopic enteral SEMS insertion, other underlying disease processes may be responsible for their ongoing symptoms. All three non-responsive patients had radiologic evidence of small volume ascites, one also had peritoneal carcinomatosis, and none had other sites of more distal bowel obstruction.
Conversely, a significant proportion of patients with a successful clinical response also had radiologic evidence of small volume ascites and peritoneal disease, so these findings alone are not a reason for failure. These findings are consistent with the results of a previous study by our group on endoscopic enteral SEMS insertion for management of malignant GOO in patients with underlying peritoneal carcinomatosis. In the absence of multifocal intestinal obstruction, SEMS placement may provide effective palliation of malignant gastric outlet obstruction, while the presence or absence of carcinomatosis or ascites did not predict clinical response [10] .
Of the patients demonstrating initial clinical success, all those who underwent subsequent endoscopic re-intervention with stent revision were able to continue oral nutritional intake for a significant duration, including three patients who received coaxial insertion of a new SEMS into a preexisting obstructed SEMS. All attempts at stent revision were successful. Our high rate of success with stent revision via second stent insertion into a preexisting stent is consistent with findings of another prior study that reported coaxial stent re-insertion in patients with malignant GOO due to inoperable gastric cancer [17] . As such, endoscopic stent revision may be considered prior to pursuing other potential palliative management options in patients with evidence of stent occlusion due to tumor in-/overgrowth following simultaneous afferent/efferent limb enteral SEMS placement in an anastomosis with recurrent malignant stricture.
There was no apparent association between SEMS insertion and a patient's ability to receive palliative chemotherapy thereafter. Patients were able to initiate or continue chemotherapy following enteral SEMS insertion. For patients who ceased chemotherapy, the decision was not related to SEMS placement. Complications were limited in our cohort. In one patient, mal-positioning of the afferent jejunal limb enteral stent was associated with afferent stent food bolus obstruction and prosthesis-related obstruction of the efferent limb stent. The patient required treatment with antibiotics and stent revision and subsequently was able to tolerate oral nutritional intake. Another patient had proximal stent migration into the gastric remnant which was successfully treated with endoscopic stent removal.
A high rate of technical and clinical success, and low incidence of complications, suggests that simultaneous endoscopic SEMS insertion into both afferent and efferent jejunal limbs is an effective and safe palliative treatment of recurrent malignancy causing GOO in the setting of postsurgical anastomosis and does not impact the ability to receive chemotherapy. The durable response rate of 48 % seen in this series is also impressive and consistent with the natural history of these diseases which are often associated with multifocal progression and development of multiple symptoms following each intervention [18] .
